SELLAS Life Sciences Group, Inc. — Director's Dealing 2025

Nov 21, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2025-11-19

Reporting Person: Kalin Katherine Bach (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-19	Common Stock	P	63400	$1.59	Acquired	104400	Direct

Footnotes

F1: The price reflects the weighted average purchase price of the shares of common stock purchased. These shares of common stock were purchased in multiple transactions at prices ranging from $1.555 to $1.625 per share. Ms. Kalin undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of common stock purchased at each price.